汇添富医疗积极成长一年持有混合A：2025年第二季度利润2.85亿元 净值增长率17.18%

Core Viewpoint - The AI Fund Huatai Medical Active Growth One-Year Holding Mixed A (009664) reported a profit of 285 million yuan in the second quarter of 2025, with a weighted average profit per fund share of 0.0982 yuan, and a net value growth rate of 17.18% during the reporting period [2]. Fund Performance - As of July 18, the fund's unit net value was 0.799 yuan, with a one-year cumulative net value growth rate of 66.18%, the highest among its peers [2]. - The fund's performance over different time frames includes a three-month growth rate of 38.36% (31/138 among comparable funds), a six-month growth rate of 63.09% (29/138), and a three-year growth rate of -8.32% (65/107) [3]. Fund Management Strategy - The fund manager indicated adjustments in the portfolio during the second quarter, focusing on three main areas: technological innovation, self-sufficiency, and consumer recovery. The manager remains optimistic about industry opportunities driven by new technologies and has increased investments in innovative drugs [2]. - The manager also sees a favorable opportunity for domestic substitution in the medical device sector, particularly for leading companies in critical areas [2]. Fund Composition - As of June 30, the fund's average stock position over the past three years was 75.13%, lower than the industry average of 86.95% [13]. - The fund's top ten holdings include companies such as Sanofi, Innovent Biologics, and BeiGene, indicating a strong focus on the pharmaceutical and biotechnology sectors [17]. Fund Size and Metrics - The fund's size as of the end of the second quarter of 2025 was 1.922 billion yuan [14]. - The fund's maximum drawdown over the past three years was 47.16%, ranking 15th among comparable funds [10].